A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma - Hussain, Maha; Daignault, Stephanie; Agarwal, Neeraj; Grivas, Petros D.; Siefker‐Radtke, Arlene O.; Puzanov, Igor; MacVicar, Gary R.; Levine, Ellis Glenn; Srinivas, Sandy; Twardowski, Przemyslaw; Eisenberger, Mario A.; Quinn, David I.; et al. (Cancer, 2014)
Keywords: Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Biomarkers, Tumor - blood; Cadherins - blood; Carcinoma, Transitional Cell - blood; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - mortality; Carcinoma, Transitional Cell - secondary; Cetuximab; chemotherapy; cisplatin; Cisplatin - administration & dosage; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Disease-Free Survival; Female; gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Medical sciences; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Proportional Hazards Models; Treatment Outcome; Tumors; Urinary Bladder Neoplasms - blood; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - mortality; Urinary Bladder Neoplasms - pathology; urothelial carcinoma; Antineoplastic agent; Gemcitabine; Monoclonal antibody; Transitional cell carcinoma; Epidermal growth factor receptor; Randomization; Cancerology; Phase II trial; Clinical trial; Advanced stage; Cetuximab; Pyrimidine nucleoside; Platinum II Complexes; Human; Malignant tumor; Cisplatin; Immunomodulator; Alkylating agent; Chemotherapy; Treatment; urothelial carcinoma; Antimetabolic; Pyrimidine derivatives; Fluorine Organic compounds; Cancer; cetuximab; gemcitabine; cisplatin; chemotherapy